The immuno-oncology-based combinations with different types of immune checkpoint inhibitors ( PD-1/PD-L1 and CTLA-4 inhibitors such as nivolumab , pembrolizumab , atezolizumab , durvalumab , ipilimumab , tremelimumab ) , or the association of immune checkpoint inhibitors plus anti-angiogenic agents ( bevacizumab , lenvatinib , cabozantinib ) , have led to a breakthrough in the treatment of hepatocellular carcinoma .
The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma. Hepatocellular carcinoma is a poor prognosis tumor. Systemic therapies are frequently used due to frequent recurrences after surgical or radiologic treatments. Anti-angiogenic tyrosine kinase inhibitors have shown efficacy in monotherapy, but with very low rates of long survival and exceptional recovery. Immuno-oncology based on immune checkpoint inhibitors has revolutionized the systemic therapies since showing long survival rates without any tumor progression or recurrence for some patients in partial or complete response, and possibly for some patients in stable disease. However, the rate of responders under immuno-oncology monotherapy is too low to increase significantly the median overall survival of the treated patients. The immuno-oncology-based combinations with different types of immune checkpoint inhibitors ( PD-1/PD-L1 and CTLA-4 inhibitors such as nivolumab , pembrolizumab , atezolizumab , durvalumab , ipilimumab , tremelimumab ) , or the association of immune checkpoint inhibitors plus anti-angiogenic agents ( bevacizumab , lenvatinib , cabozantinib ) , have led to a breakthrough in the treatment of hepatocellular carcinoma . Indeed, the first phase-3 trial, combining atezolizumab with bevacizumab, has dramatically changed the outcome of patients. Data from several other types of combinations assessed in phase-3 trials are pending, and if positive, will drastically arm the physicians to efficiently treat the patients, and disrupt the current algorithm of hepatocellular carcinoma treatment.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma. Hepatocellular carcinoma is a poor prognosis tumor. Systemic therapies are frequently used due to frequent recurrences after surgical or radiologic treatments. Anti-angiogenic tyrosine kinase inhibitors have shown efficacy in monotherapy, but with very low rates of long survival and exceptional recovery. Immuno-oncology based on immune checkpoint inhibitors has revolutionized the systemic therapies since showing long survival rates without any tumor progression or recurrence for some patients in partial or complete response, and possibly for some patients in stable disease. However, the rate of responders under immuno-oncology monotherapy is too low to increase significantly the median overall survival of the treated patients. The immuno-oncology-based combinations with different types of immune checkpoint inhibitors ( PD-1/PD-L1 and CTLA-4 inhibitors such as nivolumab , pembrolizumab , atezolizumab , durvalumab , ipilimumab , tremelimumab ) , or the association of immune checkpoint inhibitors plus anti-angiogenic agents ( bevacizumab , lenvatinib , cabozantinib ) , have led to a breakthrough in the treatment of hepatocellular carcinoma . Indeed, the first phase-3 trial, combining atezolizumab with bevacizumab, has dramatically changed the outcome of patients. Data from several other types of combinations assessed in phase-3 trials are pending, and if positive, will drastically arm the physicians to efficiently treat the patients, and disrupt the current algorithm of hepatocellular carcinoma treatment.

            ### Response:
            nivolumab, pembrolizumab, atezolizumab, durvalumab, ipilimumab, tremelimumab, bevacizumab, lenvatinib, cabozantinib
            